Agreement between ICU clinicians and electrophysiology cardiologists on the decision to initiate a QTc-interval prolonging medication in critically ill patients with potential risk factors for torsade de pointes: A comparative, case-based evaluation

Pharmacotherapy

Volumn 33, Issue 6, 2013, Pages 589-597

  Fongemie, Justin M ^a   Al Qadheeb, Nada S ^b   Mark Estes III, N A ^a   Roberts, Russel J ^a   Temtanakitpaisan, Yutthapong ^c   Ruthazer, Robin ^a   Devlin, John W ^b  

^a TUFTS MEDICAL CENTER   (United States)

^b NORTHEASTERN UNIVERSITY   (United States)

^c METROWEST MEDICAL CENTER   (United States)

Author keywords

Adverse drug reaction; Critical care; Drug monitoring; Haloperidol; Intensive care; QTc interval prolongation; Torsade de pointes

Indexed keywords

HALOPERIDOL; METHADONE; MOXIFLOXACIN;

ARTICLE; CARDIOLOGIST; CASE STUDY; COMPARATIVE STUDY; CONTROLLED STUDY; CRITICALLY ILL PATIENT; DELIRIUM; DRUG SAFETY; ELECTROCARDIOGRAM; HEART ELECTROPHYSIOLOGY; HUMAN; HYPOKALEMIA; HYPOMAGNESEMIA; INTENSIVE CARE UNIT; MEDICAL DECISION MAKING; MEDICAL STAFF; OUTCOME ASSESSMENT; PHARMACIST; PSYCHIATRIST; QT PROLONGATION; REGISTERED NURSE; RISK FACTOR; TORSADE DES POINTES;

ANTIPSYCHOTIC AGENTS; CRITICAL ILLNESS; DECISION MAKING; DELIRIUM; HALOPERIDOL; HEALTH CARE SURVEYS; HUMANS; INTENSIVE CARE UNITS; MEDICAL STAFF, HOSPITAL; NURSING STAFF, HOSPITAL; PHARMACISTS; PROSPECTIVE STUDIES; PSYCHOMOTOR AGITATION; RISK FACTORS; TORSADES DE POINTES;

EID: 84879568650     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1002/phar.1242     Document Type: Article

References (34)

1. Sauer AJ, Newton-Cheh C. Clinical and genetic determinants of torsade de pointes risk. Circulation 2012;125(13):1684-1694.
2. Drew BJ, Ackerman MJ, Funk M, Gibler WB, Kligfield P, Menon V, et al. Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. J Am Coll Cardiol 2010;55:934-947.
3. Tisdale JE. Ventricular arrhythmias. In: Tisdale JE, Miller DA, eds. Drug-induced diseases: prevention, detection, and management, 2nd ed. Bethesda, MD: American Society of Health- System Pharmacists; 2010:485-515.
4. Pickham D, Shinn JA, Chan GK, Funk M, Drew BJ. Quasiexperimental study to improve nurses' QT-interval monitoring: results of QTIP study. Am J Crit Care 2012;21:195-200.
5. Pickham D, Helfenbein E, Shinn JA, et al. High prevalence of corrected QT interval prolongation in acutely ill patients is associated with mortality: results of the QT in practice [QTIP] study. Crit Care Med 2012;40:394-399.
6. Kannankeril PJ, Roden DM. Drug-induced long QT and torsade de pointes: recent advances. Curr Opin Cardiol 2007;22:39-43.
7. Arizona Center for Education and Research on Therapeutics. QT drug lists by risk groups. Available from http://www.azcert.org/medical-pros/drug-lists/ drug-lists.cfm]. Accessed August 17, 2012.
8. Smithburger PL, Seybert AL, Armahizer MJ, Kane-Gill SL. QT prolongation in the intensive care unit: commonly used medications and the impact of drug-drug interactions. Expert Opin Drug Saf 2010;9:699-712.
9. Susla GM, Takanishi G, Dellinger RP. Drugs used in critical care medicine. In: Parrillo JE, Dellinger RP, eds. Critical care medicine: principles of diagnosis and management in the adult, 2nd ed. St. Louis, MO: Mosby; 2002:312-368.
10. Lasser KE, Allen PD, Woolhandler SJ, Himmelstein DU, Wolfe SM, Bor DH. Timing of new black box warnings and withdrawals for prescription medications. JAMA 2002;287:2215-2220.
11. Food and Drug Administration. Guidance for industry: E14 clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. Available from http://www.fda.gov/downloads/ RegulatoryInformation/ Guidances/ucm129357.pdf. Accessed August 17, 2012.
12. Food and Drug Administration. Drug safety communication: Abnormal heart rhythms associated with high doses of Celexa [citalopram hydrobromide]. Available from http://www.fda.gov/ Drugs/DrugSafety/ucm269086.htm. Accessed August 17, 2012.
13. Hines LE, Malone DC, Murphy JE. Recommendations for generating, evaluating, and implementing drug-drug interaction evidence. Pharmacotherapy 2012;32:304-313.
14. Bertsche T, Pfaff J, Schiller P, et al. Prevention of adverse drug reactions in intensive care patients by personal intervention based on an electronic clinical decision support system. Intensive Care Med 2010;36:665-672.
15. Tisdale JE, Wroblewski HA, Overholser BR, Kingery JR, Trujillo TN, Kovacs RJ. Prevalence of QT interval prolongation in patients admitted to cardiac care units and frequency of subsequent administration of QT interval-prolonging drugs: a prospective, observational study in a large urban academic medical center in the US. Drug Saf 2012;35:459-470.
16. Devlin JW, Skrobik Y. Antipsychotics for the prevention and treatment of delirium in the intensive care unit: what is their role? Harv Rev Psychiatry 2011;19:59-67.
17. Patel RP, Gambrell M, Speroff T, et al. Delirium and sedation in the intensive care unit: survey of behaviors and attitudes of 1,384 healthcare professionals. Crit Care Med 2009;37:825-832.
18. Huyse F, van Schijndel RS. Haloperidol and cardiac arrest. Lancet 1988;2:568-569.
19. Sharma ND, Rosman HS, Padhi ID, Tisdale JE. Torsades de pointes associated with intravenous haloperidol in critically ill patients. Am J Cardiol 1998;81:238-240.
20. Food and Drug Administration. Information for healthcare professionals: Haloperidol [marketed as Haldol, Haldol decanoate and Haldol lactate]. Available from http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ DrugSafetyInformationforHeathcareProfessionals/ucm085203.htm. Accessed August 17, 2012.
21. Meyer-Massetti C, Cheng CM, Sharpe BA, Meier CR, Guglielmo BJ. The FDA extended warning for intravenous haloperidol and torsades de pointes: how should institutions respond? J Hosp Med 2010;5:E8-E16.
22. Hassaballa HA, Balk RA. Torsade de pointes associated with the administration of intravenous haloperidol: a review of the literature and practical guidelines for use. Expert Opin Drug Saf 2003;2:543-547.
23. Muzyk AJ, Rayfield A, Revollo JY, Heinz H, Gagliardi JP. Examination of baseline risk factors for QTc interval prolongation in patients prescribed intravenous haloperidol. Drug Saf 2012;35:547-553.
24. Salerno SM, Alguire PC, Waxman HS. Competency in interpretation of 12-lead electrocardiograms: a summary and appraisal of published evidence. Ann Intern Med 2003;138:751-760.
25. Viskin S, Rosovski U, Sands AJ, et al. Inaccurate electrocardiographic interpretation of long QT: the majority of physicians cannot recognize a long QT when they see one. Heart Rhythm 2005;2:569-574.
26. Bhatia A, Nangia V, Solis J, Dhala A, Sra J, Akhtar M. Biventricular pacing and QT interval prolongation. J Cardiovasc Electrophysiol 2007;18:623-627.
27. Krantz MJ, Rowan SB, Schmittner J, Bucher Bartelson B. Physician awareness of the cardiac effects of methadone: results of a national survey. J Addict Dis 2007;26:79-85.
28. Poluzzi E, Raschi E, Moretti U, De Ponti F. Drug-induced torsades de pointes: data mining of the public version of the FDA adverse event reporting system [AERS]. Pharmacoepidemiol Drug Saf 2009;18:512-518.
29. Alqadheeb N, Roberts R, Griffin R, Garpestad E, Ruthazer R, Devlin JW. Impact of enteral methadone on the ability to wean continuously-infused opioids in critically ill, mechanically ventilated adults: a case-control study. Ann Pharmacother 2012;46:1160-1166.
30. Ng TM, Bell AM, Hong C, et al. Pharmacist monitoring of QTc interval-prolonging medications in critically ill medical patients: a pilot study. Ann Pharmacother 2008;42:475-482.
31. Ng TM, Bell AM, Hong C, et al. Making electronic prescribing alerts more effective: scenario-based experimental study in junior doctors. J Am Med Inform Assoc 2011;18:789-798.
32. Subramanian A, Timberlake M, Mittakanti H, Lara M, Brandt ML. Novel educational approach for medical students: improved retention rates using interactive medical software compared with traditional lecture-based format. J Surg Educ 2012;69:449-452.
33. Curtis JR, Cook DJ, Wall RJ, et al. Intensive care unit quality improvement: a "how-to" guide for the interdisciplinary team. Crit Care Med 2006;34:211-218.
34. Ray WA, Murray KT, Hall K, Arbogast PG, Stein CM. Azithromycin and the risk of cardiovascular death. N Engl J Med 2012;366:1881-1890.